Supriya Lifescience passes all resolutions at 18th AGM
- All five ordinary resolutions passed with requisite majority at the 18th AGM
- Final dividend of ₹1.00 per equity share declared for FY26
- Dr. Saloni Wagh reappointed despite 4.13% dissent from public institutions
- Meeting chaired by Joint MD Shivani Wagh due to Chairman's medical emergency
*this image is generated using AI for illustrative purposes only.
Supriya Lifescience Limited concluded its 18th Annual General Meeting on September 24, 2026, with all five ordinary resolutions passed with requisite majority. The meeting, held via video conferencing, approved the audited financial statements for FY26 and a final dividend of ₹1.00 per equity share.
The proceedings commenced at 3:00 pm and concluded at 3:50 pm. Dr. Satish Wagh, Chairman and Executive Director, was unable to chair the meeting due to a medical emergency. Ms. Shivani Wagh, Joint Managing Director, assumed the chair after ascertaining the quorum.
Key resolutions approved
Shareholders voted on five key items of business, all classified as ordinary resolutions:
- Adoption of audited financial statements for FY26
- Declaration of final dividend of ₹1.00 per share (50% on face value of ₹2)
- Reappointment of Dr. Saloni Wagh (DIN: 08491410) retiring by rotation
- Ratification of cost auditor remuneration for FY27
- Reappointment of Ms. Shivani Wagh (DIN: 08491420) retiring by rotation
Voting participation details
The voting results highlight significant promoter support across all resolutions. Public institutional shareholders showed notable dissent in specific director reappointments, particularly for Dr. Saloni Wagh.
| Resolution | Total Votes Polled | Votes In Favour (%) | Votes Against (%) |
|---|---|---|---|
| Adopt Financial Statements | 58,344,934 | 99.9974% | 0.0026% |
| Declare Final Dividend | 58,344,944 | 99.9973% | 0.0027% |
| Reappoint Dr. Saloni Wagh | 58,140,184 | 99.7621% | 0.2379% |
| Ratify Cost Auditor Remuneration | 58,344,944 | 99.9963% | 0.0037% |
| Reappoint Ms. Shivani Wagh | 55,367,537 | 99.9958% | 0.0042% |
What the numbers show
A divergence in voting patterns emerged during the reappointment of Dr. Saloni Wagh. While promoters voted unanimously in favor, public institutions cast 136,499 votes against her reappointment, representing 4.13% of the votes polled by that category. This contrasts sharply with the near-unanimous support for the dividend declaration and financial statement adoption, where dissent from public institutions was zero. This suggests specific concerns among institutional investors regarding this particular director appointment, distinct from their broader approval of company performance metrics.
Historical Stock Returns for Supriya Lifescience
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.44% | +9.39% | +23.59% | +74.57% | +32.90% | +152.07% |
Will the 4.13% dissent from institutional investors against Dr. Saloni Wagh's reappointment trigger a review of board independence or governance standards in the next fiscal year?
How might the Chairman's medical absence and the subsequent leadership transition to Ms. Shivani Wagh influence strategic decision-making continuity in FY27?
What impact will the approved cost auditor remuneration for FY27 have on Supriya Lifescience's operational expense structure and margin stability?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
